Annegret de Baey-Diepolder

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland.

Gimv Life Sciences (Gimv-LS) is the venture capital division of Belgium's Gimv NV (XB: GIMB), an investment firm founded in 1980. Based in Antwerp, Gimv-LS manages a variety of funds which focus on investing in European companies in the life sciences / biotech sector, including the Biotech Fonds Vlaanderen, which was established at the request of the Flemish Region to provide venture capital to existing and start-up medium and large-sized companies in the Flemish biotechnology sector.

TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.